vs
Side-by-side financial comparison of American Assets Trust, Inc. (AAT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $110.6M, roughly 1.6× American Assets Trust, Inc.). American Assets Trust, Inc. runs the higher net margin — 6.1% vs 1.6%, a 4.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.8%). Over the past eight quarters, American Assets Trust, Inc.'s revenue compounded faster (-0.1% CAGR vs -0.2%).
Personal Assets Trust is a large British investment trust. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The chairman is Iain Ferguson CBE.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AAT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $110.6M | $177.4M |
| Net Profit | $6.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 23.4% | 3.9% |
| Net Margin | 6.1% | 1.6% |
| Revenue YoY | 1.8% | 5.0% |
| Net Profit YoY | -16.3% | — |
| EPS (diluted) | $0.08 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $110.6M | $177.4M | ||
| Q4 25 | $110.1M | $196.9M | ||
| Q3 25 | $109.6M | $179.5M | ||
| Q2 25 | $107.9M | $181.1M | ||
| Q1 25 | $108.6M | $168.9M | ||
| Q4 24 | $113.5M | $187.3M | ||
| Q3 24 | $122.8M | $168.6M | ||
| Q2 24 | $110.9M | $178.0M |
| Q1 26 | $6.7M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $4.5M | $5.4M | ||
| Q2 25 | $5.5M | $-4.8M | ||
| Q1 25 | $42.5M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $16.7M | $-143.5M | ||
| Q2 24 | $11.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 59.4% | 79.5% | ||
| Q3 25 | 60.5% | 80.9% | ||
| Q2 25 | 62.6% | 77.4% | ||
| Q1 25 | 62.0% | 79.7% | ||
| Q4 24 | 61.3% | 78.7% | ||
| Q3 24 | 65.5% | 76.9% | ||
| Q2 24 | 63.6% | 75.1% |
| Q1 26 | 23.4% | 3.9% | ||
| Q4 25 | 21.1% | 1.2% | ||
| Q3 25 | 22.6% | 3.5% | ||
| Q2 25 | 24.1% | 4.7% | ||
| Q1 25 | 66.3% | 1.2% | ||
| Q4 24 | 26.5% | 13.2% | ||
| Q3 24 | 30.8% | -82.8% | ||
| Q2 24 | 27.8% | 15.9% |
| Q1 26 | 6.1% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.1% | 3.0% | ||
| Q2 25 | 5.1% | -2.7% | ||
| Q1 25 | 39.2% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.6% | -85.1% | ||
| Q2 24 | 10.7% | 10.6% |
| Q1 26 | $0.08 | $0.07 | ||
| Q4 25 | $0.06 | $0.05 | ||
| Q3 25 | $0.07 | $0.12 | ||
| Q2 25 | $0.09 | $-0.11 | ||
| Q1 25 | $0.70 | $0.10 | ||
| Q4 24 | $0.14 | $0.38 | ||
| Q3 24 | $0.28 | $-3.11 | ||
| Q2 24 | $0.20 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $653.9M |
| Total Assets | $2.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $118.3M | $144.3M | ||
| Q4 25 | $129.4M | $238.4M | ||
| Q3 25 | $138.7M | $246.3M | ||
| Q2 25 | $143.7M | $445.9M | ||
| Q1 25 | $143.9M | $493.6M | ||
| Q4 24 | $425.7M | $484.6M | ||
| Q3 24 | $533.0M | $453.8M | ||
| Q2 24 | $114.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $2.0B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | $653.9M | ||
| Q4 25 | $1.2B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.2B | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | $1.2B | $778.3M | ||
| Q3 24 | $1.2B | $749.6M | ||
| Q2 24 | $1.2B | $879.3M |
| Q1 26 | $2.9B | $1.2B | ||
| Q4 25 | $2.9B | $1.3B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | $3.0B | $1.5B | ||
| Q1 25 | $3.0B | $1.6B | ||
| Q4 24 | $3.3B | $1.6B | ||
| Q3 24 | $3.4B | $1.5B | ||
| Q2 24 | $3.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.48× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.72× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AAT
| Rental income | $104.4M | 94% |
| Other | $6.2M | 6% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
